Cargando…

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis

BACKGROUND: Oral miltefosine has been shown to be non-inferior to first-line, injectable meglumine antimoniate (MA) for the treatment of cutaneous leishmaniasis (CL) in children. Miltefosine may be administered via in-home caregiver Directly Observed Therapy (cDOT), while patients must travel to cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berger, Brandon A., Cossio, Alexandra, Saravia, Nancy Gore, Castro, Maria del Mar, Prada, Sergio, Bartlett, Allison H., Pho, Mai T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404883/ https://www.ncbi.nlm.nih.gov/pubmed/28384261 http://dx.doi.org/10.1371/journal.pntd.0005459

Ejemplares similares

Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study
por: Castro, Maria del Mar, et al.
Publicado: (2017)

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)
por: Gómez, María Adelaida, et al.
Publicado: (2020)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions
por: Regli, Ivo B., et al.
Publicado: (2018)

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
por: Castro, María del Mar, et al.
Publicado: (2017)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
por: Yazdanpanah, Mohamad Javad, et al.
Publicado: (2011)

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
por: Vasconcellos, Erica de Camargo Ferreira e, et al.
Publicado: (2014)

Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia
por: Rojas Cabrera, Ernesto, et al.
Publicado: (2022)

The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate
por: Omidian, Mohammad, et al.
Publicado: (2019)

Neutrophil Activation: Influence of Antimony Tolerant and Susceptible Clinical Strains of L. (V.) panamensis and Meglumine Antimoniate
por: Fernández, Olga Lucía, et al.
Publicado: (2021)

Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate
por: Perez-Franco, Jairo E., et al.
Publicado: (2016)

The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial
por: Tayyebi, Masoumeh, et al.
Publicado: (2021)

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
por: Layegh, Pouran, et al.
Publicado: (2011)

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
por: Ribeiro, Madelon Novato, et al.
Publicado: (2014)

Dressings Combined with Injection of Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial
por: Khatami, Alireza, et al.
Publicado: (2013)

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
por: LYRA, Marcelo Rosandiski, et al.
Publicado: (2016)

Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran
por: Aflatoonian, Mohammad Reza, et al.
Publicado: (2019)

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
por: Berenguer, Diana, et al.
Publicado: (2019)

Therapeutic Potential of Green Synthesized Copper Nanoparticles Alone or Combined with Meglumine Antimoniate (Glucantime(®)) in Cutaneous Leishmaniasis
por: Albalawi, Aishah E., et al.
Publicado: (2021)

Meglumine Antimoniate and Miltefosine Combined With Allopurinol Sustain Pro-inflammatory Immune Environments During Canine Leishmaniosis Treatment
por: Santos, Marcos Ferreira, et al.
Publicado: (2019)

Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
por: da Silva, Rosiana Estéfane, et al.
Publicado: (2016)

American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate
por: Senchyna, A., et al.
Publicado: (2020)

Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis
por: Brito, Nayara C., et al.
Publicado: (2019)

Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol
por: Manna, Laura, et al.
Publicado: (2015)

Evaluation of a Possible Synergistic Effect of Meglumine Antimoniate with Paromomycin, Miltefosine or Allopurinol on in Vitro Susceptibility of Leishmania tropica Resistant Isolate
por: REZAEI RIABI, Tahereh, et al.
Publicado: (2013)

Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
por: Fernández, Olga Lucía, et al.
Publicado: (2014)

Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients
por: de Oliveira Bezerra, Débora Cristina, et al.
Publicado: (2017)

SUCCESSFUL TREATMENT OF MULTIFOCAL CUTANEOUS LEISHMANIASIS WITH MILTEFOSINE
por: Madke, Bhushan, et al.
Publicado: (2011)

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
por: Valete-Rosalino, Cláudia Maria, et al.
Publicado: (2014)

Therapeutic Effect of Sodium Selenite and Zinc Sulphate as Supplementary with Meglumine Antimoniate( Glucantime®) Against Cutaneous Leishmaniasis In BALB/C Mice
por: Sorkhroodi, F Zamani, et al.
Publicado: (2010)

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
por: Ramalho, Dario Brock, et al.
Publicado: (2018)

The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of Leishmania tropica
por: MAHMOUDVAND, Hossein, et al.
Publicado: (2017)

Trypanothione Reductase Gene Mutations in Meglumine Antimoniate Resistant Isolates from Cutaneous Leishmaniasis Patients Using Molecular Dynamics Method
por: FOZONGARI, Fatemeh, et al.
Publicado: (2020)

Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2019)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Effect of hydroalcoholic extract of Echinacea purpurea in combination with meglumine antimoniate on treatment of Leishmania major-induced cutaneous leishmaniasis in BALB/c mice
por: Sarkari, Bahador, et al.
Publicado: (2017)

Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?
por: Leite-Silva, Jéssica, et al.
Publicado: (2023)

Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate
por: Guarneri, Claudio, et al.
Publicado: (2017)

Comparison of Intralesional Meglumine Antimonite along with oral Itraconazole to Intralesional Meglumine Antimonite in the treatment of Cutaneous Leishmaniasis
por: Bashir, Uzma, et al.
Publicado: (2019)

Correction: Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7fm0cou37tpp17fl20n0h2a0ao